Mechanistic insights toward dissociating therapeutic from psychedelic effects: bridging the gap between psychedelic research and mental health care

Clinical trials investigating psychedelic compounds for depression and anxiety-related disorders are yielding promising preliminary results. Psychedelics produce profound alterations in brain function-such as suppression of the default mode network and thalamocortical dysregulation-leading to intense subjective experiences including ego dissolution and mystical-type states. While often described as meaningful or therapeutic, these effects can also be unpredictable or distressing. Because of these effects, which require labor-intensive, potentially cost-challenging preparation, administration, integration sessions, and exclude individuals with psychiatric vulnerabilities (e.g., bipolar disorder, borderline personality disorder, schizophrenia), questions remain about their real-world scalability. Consequently, there is growing interest in the possibility of dissociating the therapeutic benefits of psychedelics from their consciousness-altering effects. In this perspective, we examine emerging clinical and preclinical evidence investigating this scientifically timely and pressing question. Pharmacological strategies such as serotonin 2A receptor (5-HT2A R) antagonism and the development of “biased” psychedelic analogues or psychedelic-inspired compounds with reduced or null psychedelic potential may represent potential routes through which therapeutic efficacy may be retained even in the absence of psychedelic experiences. Current preclinical data suggest that downstream molecular and network-level mechanisms may mediate therapeutic effects independently of 5-HT2A R-driven subjective states. Whether these mechanisms can fully substitute for the experiential component of psychedelic therapy remains to be determined. Nonetheless, confirming this dissociation could mark a turning point in psychopharmacology, enabling the development of next-generation psychedelic-inspired treatments that may be more scalable, accessible, and appropriate for a broader range of psychiatric populations.